FUNI · XBRL financial data

Hypha Labs financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FUNI's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue from contracts with customers	2,574	2,504	2,700	—	—	—
Cost of goods and services sold	1,779	1,789	1,634	—	—	—
Gross profit	796	715	1,066	—	—	—
General and administrative	1,483	934	1,359	103	944	1,417
Total operating expenses	2,988	1,488	2,080	437	1,827	3,001
Operating income (loss)	(2,192)	(772)	(1,014)	(437)	(1,827)	(3,001)
Interest expense	148	145	260	364	202	106
Other income (expense)	81	—	—	(55)	14	(20)
Income tax expense (benefit)	—	—	—	—	14	—
Net income (loss)	(2,309)	(687)	(2,057)	247	(785)	(3,102)
Earnings per share, basic USD per share	—	(0.01)	(0.03)	0.00	(0.01)	(0.02)
Earnings per share, diluted USD per share	—	—	(0.03)	0.00	(0.01)	(0.02)
Weighted average shares, basic thousands of shares	—	65,868	74,173	83,925	101,349	135,146
Weighted average shares, diluted thousands of shares	—	—	74,173	83,925	101,349	135,146

Fiscal years (FUNI's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	83	296	56	271	91	38
Accounts receivable	242	215	335	—	—	—
Prepaid and other current assets	54	60	—	—	289	27
Total current assets	397	827	562	766	410	321
Property and equipment, net	885	647	461	—	27	63
Right-of-use asset	506	414	317	—	57	26
Goodwill	593	—	—	—	—	—
Total assets	1,788	1,888	1,340	1,409	494	409
Accounts payable	388	371	550	122	86	473
Accrued liabilities	163	220	378	—	—	—
Total current liabilities	773	2,014	2,954	3,122	1,394	2,512
Lease liability, non-current	424	330	230	—	27	—
Total liabilities	2,878	2,941	3,749	3,281	1,420	2,512
Accumulated deficit	(17,265)	(17,952)	(20,009)	(19,762)	(20,547)	(23,649)
Total stockholders' equity	(1,089)	(1,053)	(2,743)	(2,205)	(1,260)	(2,437)
Total liabilities and equity	1,788	1,888	1,340	1,409	494	409
Common shares outstanding (cover page) thousands of shares	64,065	72,730	75,147	87,097	126,547	155,522

Fiscal years (FUNI's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(2,309)	(687)	(2,057)	247	(785)	(3,102)
Stock-based compensation	—	404	566	59	734	1,850
Depreciation and amortization	323	292	204	—	—	—
Net cash from operating activities	(672)	(136)	(185)	113	(1,034)	(380)
Purchases of property and equipment	141	56	18	—	28	33
Net cash from investing activities	(341)	(286)	(660)	263	2,146	(33)
Proceeds from issuing common stock	57	20	56	—	—	76
Net cash from financing activities	772	635	605	(161)	(1,292)	360
Net change in cash	(241)	213	(240)	215	(180)	(53)

SIC 8734 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8734 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Hypha Labs	5.1	not reported	(52)*	163.9M	0.1 quarters	Q3 FY26 10-QJun 30, 2026
Cannabis Bioscience International Holdings	0.1	11	(15)*	11.6B	0.0 quarters	Q3 FY26 10-QFeb 28, 2026
iSpecimen	4,414	152	(690)*	2.5M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Foxo Technologies	58	4,715	299*	1.7M	—	Q2 FY26 10-QJun 30, 2026
Weed	1.1	0	(19)*	148.3M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
OneMedNet	358	292	(1,875)*	59.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
IB Acquisition	30	not reported	(474)*	5.0M	0.1 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.